Canopy Growth’s Strategic Pivot: A Critical Juncture

The Canadian cannabis producer Canopy Growth is approaching a significant milestone in its multi-year strategic overhaul. The company’s path to potential profitability hinges on two recent developments: the imminent finalization of its acquisition of MTL Cannabis Corp. and a substantially narrowed quarterly loss. The central question for investors is whether this transaction can provide the necessary lift to the company’s margins.

Financial Performance: Shrinking Losses Amid Stable Revenue

For its third fiscal quarter of 2026, covering the period ending December 31, 2025, Canopy Growth reported a largely stable net revenue of CA$74.5 million. More notably, the bottom line showed measurable improvement. The net loss per share contracted sharply to CA$0.18, a significant reduction from the CA$1.11 loss recorded in the same quarter a year earlier.

Operational metrics also reflected progress. The adjusted EBITDA loss narrowed to CA$3 million, which the company stated was its best performance to date. Within the Canadian market, the medical cannabis segment grew by 15% to reach CA$23 million, while recreational sales increased by 8% to an identical CA$23 million.

However, margin performance presented a mixed picture. The gross margin for the cannabis business declined to 25%, down from 28% in the prior-year period. Management attributed this contraction to reduced international sales and a shift in product sales mix. The company also noted that potential changes to a veterans’ reimbursement program could further impact margins.

Segment Highlights: Vaporizer Strength Offsets International Weakness

A standout performer was the company’s vaporizer subsidiary, Storz & Bickel. The division’s net revenue surged by 45% compared to the previous quarter, driven primarily by robust sales of the new VEAZY vaporizer device.

Conversely, the international business segment acted as a drag on overall margins. This dynamic underscores that the recent operational advances have been primarily fueled by the domestic Canadian market and the accessories business, rather than global expansion.

Should investors sell immediately? Or is it worth buying Canopy Growth?

The MTL Acquisition: Near-Unanimous Shareholder Approval

The pending acquisition of MTL Cannabis Corp. represents the most critical near-term catalyst. Canopy announced that MTL’s shareholders have approved the transaction at a special meeting, with an overwhelming 99.97% of votes cast in favor. Shareholder participation was high, with approximately 89% of eligible voters taking part.

The deal remains subject to customary closing conditions, including final court approval and certain third-party consents. Canopy anticipates completing the transaction before the end of March.

CFO Thomas Stewart projected that the combined entity would achieve a gross margin in the mid-to-high 30% range in the near future. He highlighted that MTL has historically operated with higher margins than Canopy, and the integration is expected to enhance both gross margin and adjusted EBITDA. The company’s target remains achieving positive adjusted EBITDA in fiscal year 2027.

As of the turn of the year, Canopy held CA$371 million in cash. Furthermore, a recapitalization completed in January extended the maturity dates for all outstanding debt to 2031.

Despite these strategic moves, the long-term share price trend remains a concern. Five years ago, the stock traded above US$300, compared to recent levels below US$2. Over the past twelve months, the share price has declined by approximately 40%, underperforming the broader cannabis sector, which fell 16% over the same period.

Consequently, the market is likely to focus on two key deliverables: the timely closure of the MTL acquisition by the end of March, and tangible evidence that Canopy can solidify its promised path toward positive adjusted EBITDA in FY2027 through improved margins.